MARAbio Systems, a tech-enabled precision immunology company, has received $19 million in Series A financing led by MAK Capital One, LLC.MAK Capital’s Michael A. Kaufman and Craig Nemiroff will join MARAbio’s board of directors.
The…
Three NHS Scotland Boards have gone live with the Evolution vLab Laboratory Information Management System by Magentus, seamlessly connecting laboratory medicine services across multiple sites to deliver streamlined workflows, greater clinical safety and better…
Continue Reading
A major pathology transformation programme in Northern Ireland took a step forward recently with both Belfast Health and Social Care Trust and South Eastern Health and Social Care Trust deploying Clinisys WinPath within days…
Continue Reading
What You Should Know:
– Emory University has launched the Emory Empathetic AI for Health Institute as part of its AI.Humanity initiative to leverage AI and big data to transform healthcare globally.
– The institute aims…
Continue Reading
Shani Bocian, co-founder and CEO of allergy telehealth company Allermi, is a “lifelong allergy sufferer.”
“I’ve had allergies since I was a little baby … I’ve always had nasal issues and nasal congestion and eczema…
AbbVie, Gilead Sciences, Pfizer, and Roche are among the companies that must cut a check to the U.S. government. Those companies have Medicare-covered medicines whose prices rose faster than inflation and according to a…
Continue Reading
Seagen, the biotech company Pfizer is buying for $43 billion, is considered a pioneer in the class of cancer drugs called antibody drug conjugates. But the first ADC to reach the market wasn’t a…
Continue Reading
The market for mobile health devices is rapidly changing with the development of smartphones, wearable watches, patient monitoring devices, and even rings and wristbands that monitor patient vital signs like heart rate, body temperature,…
Continue Reading
SetPoint Medical, a medtech company based in California, is developing a neuromodulatory device that is intended to treat rheumatoid arthritis. The overlap between the nervous and immune systems is increasingly appreciated, and this technology…
Continue Reading
Grifols, a company that turns blood plasma into therapies for immunological disorders and other conditions, is laying off about 2,000 U.S. workers as part of a corporate restructuring projected to yield up to €400 million in annual cost savings, the biotech announced Wednesday.
The layoffs represent about 8% of the Barcelona-based company’s global workforce, but they will happen mainly in its U.S. plasma operations. That’s notable because as a company that relies on plasma, the U.S. is vital to its business. The starting point for Grifols’s therapies is blood plasma. Key to its drug-making process is fractionation, in which the protein components…
